Trajan Scientific and Medical to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.

Trajan Scientific and Medical to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.

October 10, 2022

Trajan Scientific and Medical, (“Trajan”) and the Baker Heart and Diabetes Institute, (“the Baker Institute”), have reached an in-principle understanding for Trajan to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.

Dr Andrew Gooley, Trajan’s Chief Scientific Officer stated, “Led by Professor Peter Meikle, the Baker Institute has developed an AI-based approach using ‘omics’ data that can stratify groups at risk of cardiovascular disease.  The level of detail delivered by the AI-tool we understand has the potential to allow cardiologists to differentiate between patients requiring therapeutic intervention from those that can address their risk through diet and exercise.  The tool measures hundreds of biomarkers as indicators of an individual’s metabolic health and uses this to identify their metabolic age and cardiovascular risk level.”

The scope of the agreement involves Trajan supporting the Baker Institute through the validation of the Institute methodology and algorithms as an in-house IVD which will be commercialized through the Trajan Analytical Services (TAS) business unit.

A key development of the collaboration will be the translation of the Baker Institute’s wet plasma method onto Trajan’s microsampling devices and the subsequent automation of the associated sample preparation processes and their integration into what is intended to become the Trajan Clinical Lipidomics Platform.

Both parties’ intention is to see the Baker Institute’s metabolic risk score measurement capabilities translated into practice – first through the provision of the measurement service through Trajan’s laboratory located in Ringwood, (that is intending to achieve accreditation this calendar year) and secondly through the installation and support of a Trajan Clinical Lipidomics Platform to those 3rd parties who wish to provide the service.

Stephen Tomisich CEO and Managing Director of Trajan said “collaborating with Australia’s leading medical research community to translate their exciting research outcomes into practice is what drives Trajan’s vision of delivering science that benefits people. The Baker Institute’s innovative approach leveraging AI-based algorithms will potentially enable cardiologists to have their patient’s blood microsample assessed for cardiovascular risk, delivering a better outcome for patients and easing the burden on the healthcare ecosystem.”